Semaglutide is a GLP-1 receptor agonist — a class of medications that mimic the natural hormone glucagon-like peptide-1 produced in your gut after eating. Originally developed by Novo Nordisk and approved by the FDA for both type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy), semaglutide has become the most widely prescribed weight loss medication in the world.
The medication works through three complementary mechanisms. First, it acts on appetite centers in the brain — specifically the hypothalamus and brainstem — to reduce hunger and increase satiety signals. Second, it slows gastric emptying, meaning food stays in your stomach longer, helping you feel full with smaller portions. Third, it improves insulin sensitivity and blood sugar regulation, which is especially beneficial for patients with prediabetes or metabolic syndrome.
In the landmark STEP 1 clinical trial published in the New England Journal of Medicine (2021), patients receiving semaglutide 2.4mg achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo. The SELECT trial (2023) demonstrated an additional cardiovascular benefit: a 20% reduction in major adverse cardiovascular events including heart attack and stroke.
To put the trial figures in context: a 15–18% reduction for a 200-pound individual would be roughly 30–36 pounds. These are figures reported in published trials, not results GLP3 Weight Loss offers or promises. Whether semaglutide is appropriate for you, and what to expect, is a decision only an independent licensed provider can make.